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Deconstructing 
I
 
 
 
B kinase
 
On page 1677, Ruocco et al. show that the for-
mation of bone-resorbing osteoclasts is crippled
when the 
 
 
 
 subunit of the NF-
 
 
 
B–activating I
 
 
 
B
kinase (IKK) complex is missing. The absence of
IKK
 
 
 
 also protected mice against inflammatory-
induced bone loss, a complication of inflammatory
diseases such as rheumatoid arthritis (RA) that
is caused by excessive activation of osteoclasts.
The osteoclast growth factor RANKL
(receptor activator of NF-
 
 
 
B ligand) activates
the transcription factor NF-
 
 
 
B, which promotes
osteoclast development. NF-
 
 
 
B activation
requires the upstream IKK complex (IKK
 
 
 
,
 
 
 
, 
 
 
 
), which releases NF-
 
 
 
B from its inhibitor
protein. Although a recent report showed that
the IKK complex is required for osteoclast
development, the relative importance of the
two catalytic subunits of IKK (
 
 
 
, 
 
 
 
) in this
process remained unclear.
Ruocco et al. now show that mice lacking
IKK
 
 
 
 were unable to generate osteoclasts and
developed severe osteopetrosis (increased bone
formation), whereas those lacking IKK
 
 
 
 activ-
ity had no apparent bone abnormalities. The
IKK
 
 
 
-deficient mice failed to transmit RANKL
signals and had increased TNF-induced apoptosis
in osteoclast precursors. Osteoclast formation
was partially restored in mice that lacked both
IKK
 
 
 
 and the type I TNF receptor.
IKK
 
 
 
-deficient mice were also resistant to
inflammatory bone loss and this resistance was
dependent on TNF-derived signals. Thus the
authors suggest that drugs designed to block
IKK
 
 
 
 may prevent bone loss in patients. How-
ever, they caution that such drugs, if developed,
should perhaps not be combined with anti-TNF
therapy (commonly used to treat RA) as the
combination may not be effective.
The   subunit of the I B kinase complex is required 
for inflammation-induced bone loss (arrows).
 
Protecting sight with F4/80
 
On page 1615, Lin and colleagues show that an adhesive glycoprotein is 
essential to prevent the immune system from reacting to environmental 
antigens encountered by the eyes. The authors show that this glycoprotein, 
known as F4/80, induces CD8
 
 
 
 regulatory T (T reg) cells thus protecting the eye 
and perhaps other immune-privileged sites from immune attack.
The F4/80 glycoprotein was first described 
over two decades ago and has since served as a 
sensitive marker of resident tissue macrophages. 
However, this protein had no identified function 
or ligand. Previous studies by this group showed 
that F4/80
 
 
 
 antigen presenting cells (APCs) 
carry antigens from the eye to the spleen. Once 
there, the APCs induce the development of CD8
 
 
 
 
T reg cells, which in turn inhibit the activation of 
pathogenic CD4
 
 
 
 T cells and B cells.
Lin et al. now show a direct role for the F4/80 
protein in tolerance induction, as mice lacking this 
protein fail to generate CD8
 
 
 
 T reg cells after 
ocular antigen challenge. Although the mechanism 
is unknown, the structure of F4/80—with adhesive 
epidermal growth factor domains at one end and a 7-transmembrane spanning 
domain at the other—suggests that it may be involved in cell–cell or cell–matrix 
interactions and may also trigger intracellular signaling. The presence of F4/80
 
 
 
 
cells in other immune privileged sites, such as the brain and placenta, and its 
exclusion from T cell zones in the spleen suggests that F4/80 expression and 
immune activation may be mutually exclusive.
The glycoprotein F4/80 
(brown) is required for the 
induction of CD8  T reg 
cells that prevent immune 
attack on the eye.
 
Fueling CD4
 
 
 
 T cells
 
CD4
 
 
 
 T cells continuously monitor antigen levels in their environment
and adjust their expansion accordingly, as shown on page 1555. Obst
and colleagues demonstrate that when antigen runs out, CD4
 
 
 
 T cell
proliferation stops dead in its tracks.
CD8
 
 
 
 T cells have been argued to undergo multiple rounds of cell
division and to acquire effector function after only a brief encounter with
antigen. Whether CD4
 
 
 
 T cells behave similarly remains controversial.
Previous studies—mostly performed in vitro—have produced evidence
both for and against a need for prolonged antigen stimulation for sustained
CD4
 
 
 
 cell proliferation.
Obst et al. tackled this question in vivo by making a mouse in
which expression of a CD4
 
 
 
 T cell epitope could be turned on and off
using an antibiotic-inducible promoter. Using this on–off model, they
showed that antigen withdrawal resulted in the rapid cessation of
CD4
 
 
 
 T cell proliferation, even in the presence of an inflammatory
stimulus. CD4
 
 
 
 T cells stimulated in vivo for 48 hours divided only
once if transferred into an antigen-free host. This suggested that CD4
 
 
 
T cells, unlike CD8
 
 
 
 T cells, require continued presence of antigen
for continued activation.
The need for persistent antigen by CD4
 
 
 
 T cells may reflect a threshold
of signaling molecules that is required for continued activation of the cell.
Experiments to test this idea are underway. The authors also plan to test
CD8
 
 
 
 T cell activation in a similar system to determine whether the rules
governing the proliferation of these cell subsets are truly distinct.
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